Study Enrollment

Your details will not be published or shared.

Clinical Trial

MK-8591A-018: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

This study will look at HIV-positive persons whose HIV is fully suppressed, who switch immediately from their current HIV regimen to the study drug, compared to those who remain on their current regimen. It will look at both HIV response to the new regimen, as well as the safety and tolerability of the new drug.

Eligibility Criteria

  • INCLUSION: 1. Adults age 18 and old whose HIV-1 infection has been fully suppressed (<50) on a regiman containing Biktarvy (BIC/FTC/TAF) for at least 3 months, with no history of treatment failure in the past. 2. Negative pregnancy test for women who can get pregnant. EXCLUSION: 1. Has HIV-2 infection, with hypersensitivity or other problem with the study drug or its ingredients. 2. Current or past history of medical conditions not allowed by the study, required use of medications not allowed, or lab values outside of required ranges.

Contact Information

    Marti Farrough

    (706) 723-0106